Clinical and Electroencephalographic Features of the Seizures in Neuronal Surface Antibody-Associated Autoimmune Encephalitis.

Yan Wang, Yi Yu, Yaping Hu, Ying Li, Fan Song, Ying Wang
Author Information
  1. Yan Wang: Department of Neurology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
  2. Yi Yu: Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
  3. Yaping Hu: Department of Neurology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
  4. Ying Li: Department of Neurology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
  5. Fan Song: Department of Neurology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
  6. Ying Wang: Department of Neurology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.

Abstract

To investigate clinical and electroencephalographic features of the seizures in different types of neuronal surface antibody (NSAb)-associated autoimmune encephalitis (AE). The clinical data of the seizures were analyzed in 18 patients with NSAb-associated AEs diagnosed in the First Affiliated Hospital of Dalian Medical University. From May 2013 to April 2019, a total of 18 cases of NSAb-associated AE were diagnosed, including 9 cases of leucine-rich glioma-inactivated 1 protein (LGI1) antibody-associated encephalitis, 7 cases of anti--methyl-d-aspartate receptor (NMDAR) encephalitis, and 2 cases of anti-γ-aminobutyric acid B receptor (GABAR) encephalitis. All nine cases (100%) with LGI1 AE had seizures manifesting in three types: faciobranchial dystonia seizure (FBDS) (44.4%), mesial temporal lobe epilepsy (MTLE)-like seizure (66.7%), and focal to bilateral tonic-clonic seizure (FBTCS) (77.8%). Six of nine (66.7%) showed abnormal signal on hippocampus or basal ganglia in brain MRI. Five of seven cases (71%) with anti-NMDAR encephalitis had seizures manifesting in three types: focal aware seizure (40%), focal-impaired awareness seizure (20%), generalized tonic-clonic seizure (GTCS) (100%), and status epilepticus (SE) (40%). Three of seven (42.8%) showed abnormalities in brain MRI. Both patients with anti-GABAR encephalitis had seizures manifesting in two types: GTCS and MTLE-like seizure, one with SE. One showed abnormal signal on left hippocampus in brain MRI. All patients (100%) with three types of AE had abnormalities in electroencephalogram (EEG), showing diffuse (4/18) or focal slow waves (14/18) in background, interictal (10/18), or ictal (6/18) epileptic discharges in the temporal or other regions; two patients with anti-NMDAR encephalitis showed delta activity or rhythm in frontotemporal region. All patients with seizures showed good response to immunotherapy except one with LGI1 AE. Most patients with NSAb-associated AE had seizures; seizure types varied between different types of AE. In LGI1 AE, the hippocampus and basal ganglia were two main targets; the corresponding seizure type was MTLE-like seizure and FBDS, respectively. Anti-NMDAR encephalitis had more generalized than focal seizures. Delta activity or rhythm in the frontotemporal region in EEG was helpful for diagnosis. Anti-GABAR encephalitis was characterized by refractory seizures as initial symptom, mainly GTCS or MTLE-like seizure. Most seizures in NSAb-associated AE showed good response to immunotherapy, and antiepileptic drugs should be considered as an add-on symptomatic treatment.

Keywords

References

  1. Neurology. 2019 May 7;92(19):e2185-e2196 [PMID: 30979857]
  2. Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3799-804 [PMID: 20133599]
  3. Medicine (Baltimore). 2016 Jul;95(28):e4244 [PMID: 27428233]
  4. Clin Neurophysiol. 2013 Dec;124(12):2354-61 [PMID: 23830005]
  5. Seizure. 2018 Jul;59:72-76 [PMID: 29754014]
  6. Epilepsia. 1999 Jan;40(1):120-2 [PMID: 9924914]
  7. Epilepsia. 2019 Aug;60(8):1508-1525 [PMID: 31283859]
  8. Neuroradiol J. 2016 Feb;29(1):30-5 [PMID: 26613928]
  9. Pharmacol Rev. 2016 Jul;68(3):563-602 [PMID: 27255267]
  10. Epilepsy Behav. 2016 Mar;56:165-9 [PMID: 26896820]
  11. Seizure. 2018 Aug;60:198-204 [PMID: 30031297]
  12. Epilepsia. 2017 Apr;58(4):531-542 [PMID: 28276064]
  13. J Clin Neurosci. 2019 Oct;68:73-79 [PMID: 31331752]
  14. Seizure. 2019 Feb;65:20-24 [PMID: 30597400]
  15. J Clin Neurol. 2016 Jan;12(1):1-13 [PMID: 26754777]
  16. J Neurol. 2019 Jan;266(1):195-206 [PMID: 30460450]
  17. J Neurol. 2013 Jun;260(6):1684-6 [PMID: 23681644]
  18. Clin Neurophysiol. 2017 Jul;128(7):1227-1233 [PMID: 28527387]
  19. Neurology. 2011 Apr 12;76(15):1355-7 [PMID: 21482953]
  20. Ann Neurol. 2011 May;69(5):892-900 [PMID: 21416487]
  21. Autoimmun Rev. 2016 Oct;15(10):970-4 [PMID: 27485013]
  22. Semin Pediatr Neurol. 2014 Sep;21(3):207-13 [PMID: 25510942]
  23. Brain. 2016 Apr;139(Pt 4):1079-93 [PMID: 26945884]
  24. Neurol Neuroimmunol Neuroinflamm. 2017 May 10;4(4):e353 [PMID: 28680914]
  25. Neurology. 2016 Oct 4;87(14):1449-1456 [PMID: 27590293]
  26. Epilepsy Behav. 2019 May;94:198-203 [PMID: 30974347]
  27. Int J Neurosci. 2017 May;127(5):379-385 [PMID: 27066808]
  28. J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1101-1106 [PMID: 30135187]
  29. Neurology. 2008 Feb 12;70(7):504-11 [PMID: 17898324]
  30. Ann Neurol. 2007 Jan;61(1):25-36 [PMID: 17262855]
  31. Lancet Neurol. 2010 Jan;9(1):67-76 [PMID: 19962348]
  32. Neurology. 2016 Aug 23;87(8):759-65 [PMID: 27466467]
  33. Int J Neurosci. 2018 Jul;128(7):627-633 [PMID: 29166136]
  34. Epilepsia. 2017 Dec;58(12):2104-2111 [PMID: 29098690]
  35. J Clin Invest. 2019 Mar 1;129(3):926-940 [PMID: 30714986]
  36. Lancet Neurol. 2016 Apr;15(4):391-404 [PMID: 26906964]
  37. Neurology. 2012 Sep 11;79(11):1094-100 [PMID: 22933737]
  38. Curr Opin Neurol. 2017 Jun;30(3):345-353 [PMID: 28234800]
  39. Curr Opin Neurol. 2017 Jun;30(3):302-309 [PMID: 28248701]
  40. Ann Neurol. 2011 Jul;70(1):179-80; author reply 180 [PMID: 21786308]
  41. Neurol Sci. 2019 Apr;40(4):769-777 [PMID: 30671737]
  42. Epilepsy Behav. 2018 Nov;88:277-282 [PMID: 30332659]
  43. Epilepsy Behav. 2017 Dec;77:90-95 [PMID: 29050866]
  44. J Neuroimmunol. 2019 Jul 15;332:64-68 [PMID: 30959339]
  45. Lancet Neurol. 2019 Nov;18(11):1045-1057 [PMID: 31326280]

Word Cloud

Created with Highcharts 10.0.0seizureseizuresencephalitisAEpatientscasesshowedantibodyLGI1typesNSAb-associatedfocal100%manifestingthreetypes:hippocampusbrainMRIGTCStwoMTLE-likeclinicaldifferentneuronalsurfaceautoimmune18diagnosedreceptorNMDARnineFBDStemporal667%tonic-clonic8%abnormalsignalbasalgangliasevenanti-NMDAR40%generalizedSEabnormalitiesoneEEGactivityrhythmfrontotemporalregiongoodresponseimmunotherapyinvestigateelectroencephalographicfeaturesNSAb-associateddataanalyzedAEsFirstAffiliatedHospitalDalianMedicalUniversityMay2013April2019totalincluding9leucine-richglioma-inactivated1proteinantibody-associated7anti--methyl-d-aspartate2anti-γ-aminobutyricacidBGABARfaciobranchialdystonia444%mesiallobeepilepsyMTLE-likebilateralFBTCS77SixFive71%awarefocal-impairedawareness20%statusepilepticusThree42anti-GABAROneleftelectroencephalogramshowingdiffuse4/18slowwaves14/18backgroundinterictal10/18ictal6/18epilepticdischargesregionsdeltaexceptvariedmaintargetscorrespondingtyperespectivelyAnti-NMDARDeltahelpfuldiagnosisAnti-GABARcharacterizedrefractoryinitialsymptommainlyantiepilepticdrugsconsideredadd-onsymptomatictreatmentClinicalElectroencephalographicFeaturesSeizuresNeuronalSurfaceAntibody-AssociatedAutoimmuneEncephalitisGABABR

Similar Articles

Cited By